Sorrento Therapeutics (SRNE) Reports FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
Tweet Send to a Friend
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
